



Note: In Phase 3, Carraguard™ is included however the protocol is “in preparation”.

SOURCE: Alliance for Microbicide Development. Microbicide Clinical Trials Update, 2003. Silver Spring, MD, USA: Alliance for Microbicide Development, August 2003.

Table 1. Summary of Microbicide Products in Clinical Trials (by primary endpoints)			
	HIV Reduction	Non-HIV STI Reduction	Contraceptive Efficacy
Phase 1	Acidform™, benzalkonium chloride, calanolide A, cellulose acetate phthalate, Ushercell™, human monoclonal antibodies, polystyrene sulfonate, Praneem polyherbal formulations, VivaGel™, tenofovir™ <i>Total = 10</i>	BufferGel™ ¹ , Emmelle™ ² <i>Total = 2</i>	
Phase 1/2	Invisible Condom™ <i>Total = 1</i>		
Phase 2	Emmelle™, Lactin Vaginal Capsule <i>Total = 2</i>		
Phase 2/2B	BufferGel™, PRO2000/5™ <i>Total = 2</i>		
Phase 2/3	Cellulose Sulfate <i>Total = 1</i>	Savvy™ ³ <i>Total = 1</i>	BufferGel™, Savvy™ <i>Total = 2</i>
Phase 3	Carraguard™ Savvy™ <i>Total = 2</i>		
Totals:	18 HIV Reduction	3 Non-HIV STI Reduction	2 Contraceptive Efficacy

SOURCE: Alliance for Microbicide Development. Microbicide Clinical Trials Update, 2003. Silver Spring, MD, USA: Alliance for Microbicide Development, August 2003.

¹ bacterial vaginosis

² candida, chlamydia, gonorrhea, syphilis

³ chlamydia